Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
1/2015 not set
NeuroMed
NeuroMed Overview
NeuroMed Pharmaceuticals is offering Yac-101, a potential treatment for injuries involving neuro-degeneration. Yac-101 is based on specific and differentiating metal chelation that may prevent various types of reactive oxygen species generated directly or via metal mediation. The product also has the potential to maintain cytosolic calcium homeostasis, keep mitochondrial function following ion-loading insults, prevent cell membrane damage induced by lipid peroxidation, and preserve energy stores.
NeuroMed Pharmaceuticals is now integrated within its Canadian purchaser, Zalicus Pharmaceuticals, which was in turn was acquired by Epirus Biopharmaceuticals in July 2014, both companies located in New England, USA.
The later picture: The U.S. arm of Israel-based Taro Pharmaceuticals bought Zalicus for $3.8 million in cash and a $3.8 million limited recourse note that matures in 2017. Sun controls Taro after a series of complex negotiations that began in 2007 and reached a conclusion in 2013.
Zalicus, a subsidiary of Boston-based Epirus Biopharmaceuticals, develops biosimilar drugs, is developing a pain management drug candidate called Z944.
NeuroMed Climate Tech relevance
undefined
Companies you might be interested in
Driven by Finder AI
Latest News
No Data, yet.
Sorry, no content found under this section.
Oct 14, 2015
www.fiercepharma.com
U.S. arm of Sun Pharma's Taro buys Zalicus Pharmaceuticals of Canada